GENE ONLINE|News &
Opinion
Blog

2022-11-16| M&A

Kriya Scoops Up Redpin to Break into Neurology Gene Therapies

by Reed Slater
Share To

Gene therapy-focused Kriya Therapeutics announced its acquisition of Redpin Therapeutics on Wednesday to add epilepsy and trigeminal neuralgia gene therapy candidates to its portfolio. Kriya did not disclose any financial details, but the transaction is another step in the company’s busy year of expansion.

Banking on Redpin’s Proprietary Chemogenics Platform

A major factor in the deal is Redpin’s novel chemogenics platform, which flips traditional drug development on its head. Rather than developing a small molecule to interact with receptors, Redpin is engineering receptors to interact with recognized small molecules. 

As part of the chemogenics program, Redpin uses ion channels, proteins responsible for electrical activity in cells, to stimulate under-active neurons or inhibit over-active ones. The company’s ion channel receptors currently function with the anti-smoking agent varenicline. The company said varenicline is an attractive target for its chemogenics platform because patients tolerate it well in small doses, and the agent has exceptional brain penetration. 

Kriya hopes to leverage the unique platform and continue developing epilepsy and trigeminal neuralgia candidates. Epilepsy is a brain disorder that causes spontaneous seizures, and trigeminal neuralgia is a rare disease causing sudden, sharp facial pain attacks. 

Dr. Elma Hawkins, President, CEO, and Co-founder of Redpin said, “Kriya Therapeutics is the perfect company to take this leading ion channel-based platform forward and deliver an effective treatment option for patients. We look forward to working with the Kriya team to progress these unique targeted therapies to patients in need as rapidly as possible.”

Related Article: Kyverna’s Lupus Nephritis Cell Therapy Received FDA Clearance, Aiming for Phase 1 Trial in 2023

Kriya’s Continued Expansion

The Redpin acquisition is another deal in a busy couple of years for Kriya with partnerships and acquisitions. In addition to collaborations and purchases, Kriya closed a series C financing round this year, bringing its total capital even higher.

In January this year, Kriya acquired Warden Bio and five AAV-mediated gene therapies for glycogen storage disorders. Again, the company did not disclose any financial information but said the acquisition would serve as the foundation for its Rare Disease Division. 

Also, in January, Kriya licensed its gene therapies to the Medical University of South Carolina Foundation for Research Development to develop treatments for geographic atrophy and other ocular diseases. 

The deals and acquisitions complement Kriya’s manufacturing-focused approach. The young company already has a functioning manufacturing facility where it hopes to integrate its own therapies when ready. So far, the company has not released an entire pipeline, but it is increasing based on the acquisitions alone. 

Kriya’s acquisition of Redpin marks another exciting opportunity for gene therapy in the industry. Redpin’s unique chemogenics platform will be exciting to follow with the resources and gene therapy expertise that Kriya can provide. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pfizer and Flynn Fined £70 Million in Epilepsy Drug Price Hike Scheme
2022-07-22
A New Liquid Take On an Old Epilepsy Drug Receives FDA Approval
2022-07-19
M&A
UCB Strengthens Its Rare Disease Portfolio with Its Newest Acquisition
2022-01-20
LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!